Biopharmaceutical company Pharming Group N.V. (Euronext Amsterdam:PHARM) (NASDAQ:PHAR) announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its supplemental New Drug Application for leniolisib in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).
The application has been granted Priority Review with a PDUFA target action date of 31 January 2026.
Pharming's submission is based on positive results from a multinational Phase III study showing improvements in lymphadenopathy and naïve B cell counts over 12 weeks, indicating correction of the underlying immune defect. Safety data from eight months of treatment were also included.
If approved, leniolisib would become the first and only treatment indicated for children under 12 with APDS globally. The therapy is marketed in the United States as Joenja and received FDA approval in March 2023 for patients aged 12 years and older.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval